Related Experiment Video
Updated: May 9, 2026
08:29
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
Responding to safety issues in frontotemporal dementias.
1School of Nursing,Oregon Health Sciences University, Portland, USA. talerico@ohsu.edu
Neurology
|June 13, 2001
Summary
Frontotemporal dementia (FTD) management requires addressing behavioral issues and fall risks. This study offers a biopsychosocial model and practical strategies to enhance safety and quality of life for patients and caregivers.
Area of Science:
- Neurology
- Gerontology
- Psychiatry
Background:
- Frontotemporal dementia (FTD) progression presents significant safety challenges, including behavioral disturbances like aggression and disinhibition.
- Motor deficits in FTD increase fall risks, posing further injury hazards for patients and caregivers.
- Behavioral symptoms and fall risks in FTD can lead to caregiver stress, social embarrassment, and institutionalization.
Purpose of the Study:
- To present an integrated biopsychosocial model for assessing needs manifested through behavior in FTD.
- To discuss environmental, behavioral, and psychosocial strategies for preventing and managing FTD-related risks.
- To provide clinicians and caregivers with evidence-based interventions for individualized FTD care.
Main Methods:
- The study proposes a biopsychosocial model for needs assessment in FTD.
- It reviews environmental, behavioral, and psychosocial strategies for risk management.
- It evaluates the efficacy and risks of various need-based interventions, contrasting them with physical restraints.
Main Results:
- The biopsychosocial model guides the assessment of behavioral needs in FTD.
- Practical strategies are presented to promote function, enhance quality of life, and reduce caregiver strain.
- Research-based data highlights the inefficacy and dangers of physical restraints for FTD patients.
Conclusions:
- Individualized, need-based interventions are crucial for managing FTD safety concerns.
- A biopsychosocial approach empowers clinicians and caregivers to optimize care and safety.
- Minimizing caregiver strain and maximizing patient function are key goals in FTD management.
Related Concept Videos
01:21Association Areas of the Cortex
Association areas are regions of the cerebral cortex that do not have a specific sensory or motor function. Instead, they integrate and interpret information from various sources to enable higher cognitive processes such as memory, learning, and decision-making. Some key association areas include the following:
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...